A
Avelas Biosciences
Innovative intraoperative cancer detection with AVB 620, enhancing surgical precision and patient outcomes
About Avelas Biosciences
Avelas Biosciences is a clinical-stage oncology company dedicated to improving cancer surgery outcomes through its lead product, AVB 620. AVB 620 is a novel drug-device combination designed to detect cancer in real-time during surgery, allowing surgeons to identify and remove cancerous tissue more accurately. This technology aims to become a standard part of care in various cancer surgeries, including ovarian, colorectal, head and neck, lung, and melanoma. Avelas operates in the medical and healthcare market, primarily serving surgeons and hospitals. The company generates revenue through the development and potential future sales of its innovative cancer detection products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 58.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Oncology, Surgery, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jun 2019 | $0 | — | Undisclosed | — |
| SERIES C✓Equity / VC | Aug 2016 | $20M | $80M | Pharmstandard | — |
Growth signals
Latest recorded traffic for Avelas Biosciences is 400 monthly website visits, up 90.5% over the last three months. Avelas Biosciences's team declined 33.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Avelas Biosciences in the San Diego ecosystem
The Avelas Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Avalon Ventures
WuXi AppTec
Torrey Pines Investment
WuXi Healthcare Ventures
Series B and later1 investor entered at this stage
Pharmstandard
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avelas Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avelas Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






